scispace - formally typeset
Search or ask a question

Showing papers by "Christopher R. Vakoc published in 2010"

Patent•
Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers

[...]

Bruce Stillman1, Scott W. Lowe1, Anthony Mazurek, Johannes Zuber, Christopher R. Vakoc, Katherine McJunkin •
Cold Spring Harbor Laboratory1
29 Mar 2010
TL;DR: In this article, a mosaic mouse model was used for determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. And methods of treating soft tissue cancers were presented.
Abstract: Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter Also provided are methods of treating soft tissue cancers

18 citations

Journal Article•DOI•
PAF Is in the Cabal of MLL1-Interacting Proteins that Promote Leukemia

[...]

Nancy A. Speck1, Christopher R. Vakoc2•
University of Pennsylvania1, Cold Spring Harbor Laboratory2
15 Jun 2010-Cancer Cell
TL;DR: Researchers find that MLL1 fusions are reliant on a physical interaction with the PAF transcription elongation complex for their recruitment to chromatin and, consequently, leukemic transformation.

3 citations